Global Nuclear Medicine Market to surpass $ 6610 Mn by 2024

October 01, 2019


According to the new research report available at MarketStudyReport.com under the title ‘Global Nuclear Medicine Market Growth 2019-2024’, the worldwide nuclear medicine market is predicted to exceed US $6610 million by the year 2024.
 

Radiopharmaceuticals or nuclear medicines are radioactive compounds which are administered to patients and monitored through special imaging devices for therapeutic and diagnosis purposes. Here the radioisotope is bonded with organic compound, wherein the later carries the radioisotope to particular organs such as cells or tissues. Advancements in medical technology and rise in research & development activities will fuel the growth of nuclear medicine market.
 

As per the report, nuclear medicine market was worth US $4590 million in 2019 and is expected to grow with a CAGR of 7.6% by the year 2024. The study also provides an insightful analysis of trends, challenges, opportunities, and drivers influencing the market growth.
 

The global nuclear medicine market is examined on the basis of type, application spectrum and regional landscape. Based on the type, the market is segmented as Tc-99, In-111, Xe-133, I-123/131, Th-201, Ga-67 and others, wherein Tc-99 segment contributed largely with 51.6% share in 2015. While speaking of the application spectrum, the market is fragmented as therapeutic and diagnostic, wherein diagnostic segment dominated the nuclear medicine market with 61.23% share in 2015.
 

Request sample copy of this Report@ https://www.marketstudyreport.com/request-a-sample/1628726/
 

Considering the regional landscape, the market is divided into four major regions; Europe consists of Germany, UK, France, Italy, Spain, and Russia; China, India, Australia, Japan, Southeast Asia, and Korea fall under Asia Pacific; Americas comprises of Brazil, the U.S., Mexico, and Canada; and Egypt, Turkey, GCC Countries, South Africa, and Israel come under Middle East & Africa.
 

The prominent manufacturers operating in nuclear medicine market include Dongcheng, GE Healthcare, China Isotope & Radiation, Bracco Imaging, SIEMENS, Mallinckrodt, Eli Lilly, Lantheus Medical Imaging, Jubliant Pharma, Bayer, Nordion, Triad Isotopes, and Bayer.